Relationship Between Severity of Adverse Events of Afatinib and Its Pharmacokinetics and Pharmacogenomics for EGFR Mutation-Positive Non-Small Cell Lung Cancer

被引：0
|
作者：
Gomyo, T. [1 ]
Iihara, H. [2 ]
Hayashi, H. [3 ]
Endo, J. [1 ]
Ito, F. [1 ]
Yansase, K. [1 ]
Kaito, D. [1 ]
Sasaki, Y. [1 ]
Sakai, C. [1 ]
Fukuda, Y. [3 ]
Hirose, C. [2 ]
Sugiyama, T. [1 ]
Suzuki, A. [2 ]
Ohno, Y. [1 ]
机构：
[1] Gifu Univ, Grad Sch Med, Gifu, Japan
[2] Gifu Univ Hosp, Gifu, Japan
[3] Gifu Pharmaceut Univ, Gifu, Japan
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3936
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Rare case of de novo EGFR L718V mutation-positive non-small cell lung cancer successfully treated with afatinib
    Ito, Takanori
    Fujita, Kohei
    Saito, Zentaro
    Imakita, Takuma
    Oi, Issei
    Kanai, Osamu
    Tachibana, Hiromasa
    Mio, Tadashi
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2023, 10
  • [32] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
    Lee, Sung Yong
    Choi, Chang-Min
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Ji Young
    Kim, Young-Chul
    Oh, In-Jae
    Jung, Chi Young
    Lee, Sang Hoon
    Yoon, Seong Hoon
    Choi, Juwhan
    Jang, Tae Won
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (12) : 4353 - +
  • [33] Correction to: Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
    Kazuo Tamura
    Toshihiro Nukiwa
    Akihiko Gemma
    Nobuyuki Yamamoto
    Masaya Mizushima
    Kaori Ochai
    Rie Ikeda
    Hisaya Azuma
    Yoichi Nakanishi
    International Journal of Clinical Oncology, 2019, 24 : 1169 - 1169
  • [34] Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer
    Serritella, Anthony, V
    Bestvina, Christine M.
    THORACIC SURGERY CLINICS, 2020, 30 (02) : 137 - 146
  • [35] Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
    Pan, Jie
    Cai, Xiaoping
    Cao, Zhuo
    Pan, Jiongwei
    Zheng, Hao
    PHARMACOLOGY, 2023, 108 (01) : 8 - 16
  • [36] SCREENING FOR DRUGS THAT OVERCOME GEFITNIB RESISTANCE IN EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER CELLS
    Xue, Yibo
    Wang, Chao
    Zheng, Zhi
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S255 - S256
  • [37] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
    Moiseyenko, V.
    Procenko, S. A.
    Levchenko, E. V.
    Barchuk, A. S.
    Matsko, D. E.
    Moiseyenko, F. V.
    Ivantsov, A. O.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Imyanitov, E. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
    Haddish-Berhane, N.
    Cho, B. C.
    Ahn, M.
    Han, J.
    Kim, S.
    Lee, K. H.
    Cho, E. K.
    Mehta, J.
    Xie, J.
    Shreeve, S. M.
    Knoblauch, R. E.
    Freeman, J.
    Roshak, A.
    Jang, S. B.
    Lee, H.
    Kang, S.
    Kim, K. B.
    Oh, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S677 - S678
  • [39] Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer Cells by Targeting Survivin
    Okamoto, Kunio
    Okamoto, Isamu
    Hatashita, Erina
    Kuwata, Kiyoko
    Yamaguchi, Haruka
    Kita, Aya
    Yamanaka, Kentaro
    Ono, Mayumi
    Nakagawa, Kazuhiko
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (01) : 204 - 213
  • [40] FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Kazandjian, Dickran
    Blumenthal, Gideon M.
    Yuan, Weishi
    He, Kun
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (06) : 1307 - 1312
12345